Support for advanced diagnosis, drug efficacy and safety monitoring for central nervous system diseases
– Automated quantification of a broad portfolio of
clinically-relevant imaging markers
– Easy comparison with normative dataset of healthy subjects
– Intuitive user interface for in-depth analysis
– Automated reporting with clear-cut results
INTEGRATED WITH LEADING MRI SCANNERS AND RIS/PACS SYSTEMS
Support for advanced diagnosis, drug efficacy and safety monitoring for central nervous system diseases
– Automated quantification of a broad portfolio of
clinically-relevant imaging markers
– Easy comparison with normative dataset of healthy subjects
– Intuitive user interface for in-depth analysis
– Automated reporting with clear-cut results
CE-marked and FDA-cleared
INTEGRATED WITH LEADING MRI SCANNERS AND RIS/PACS SYSTEMS
BENEFITS
CLINICAL
Improves diagnosis, monitoring and likelihood of observing longitudinal changes by eliminating inter-/intra-rater variability.
↓ 89%*
of inter-rater variability on average for white matter lesions
COST & TIME
Reduction of time and cost of image analysis.
↓ 80%**
of time and cost compared to manual segmentation performed by experts
* Qynapse study – comparison between automated quantification of white matter lesions and expert manual segmentation – using published data (Commowick, O., Istace, A., Kain, M. et al. Sci Rep 8, 13650. 2018)
** Based on Qynapse estimation
Qynapse is a medical technology company that unlocks the potential of quantitative imaging and AI to optimize diagnosis, prognosis and longitudinal monitoring of patients with neurological diseases.
PARTNERS
